NFKB1 and lung carcinoma: Support for this hypothesis comes from studies in lung cancer showing that lung cancer cells exposed to chemotherapeutic agents exhibit enhanced NF-kB activation, which in turn sustains elevated production of IL-34 in chemoresistant cells [67].